Off-Label Prescriptions in Dermatology: Challenges of New Routes of Administration for Certain Old Drugs

被引:1
|
作者
Tasic-Kostov, Marija [1 ]
Ilic, Dusan [1 ]
机构
[1] Univ Nis, Fac Med, Dept Pharm, Nish, Serbia
关键词
off-label drug; dermatology; compounded drugs; drug vehicle; INFANTILE HEMANGIOMAS; TOPICAL PROPRANOLOL; SPIRONOLACTONE; THERAPY; SAFETY; ACNE; GEL;
D O I
10.5937/afmnai37-25282
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
"Off-label drug use" refers to the prescription of medications, with reference to indications, dosage, dosage form, patient group or route of administration, which are officially unapproved. Recently, new indications for some drugs have emerged and few of them are being used off-label to treat topically a variety of dermatological conditions. Off-label use is more common in dermatology than in other medical specialties, and those drugs are basically available as compounded formulations, but the choice of a proper vehicle and safety of extemporaneous drug preparation intended for topical use are usually neglected in case of systemic drugs. Moreover, the bases commonly used as vehicles for extemporaneous dermatological preparations are stabilized with traditional surfactants known for their potential to irritate skin, while inflammatory dermatoses can worsen when exposed to irritants In this paper, we have listed several systemic drugs which are being used in topical treatment of some frequent dermatological conditions, but not according to their officially approved indications. The choice of drugs was made according to the topical off-label dermatological prescriptions obtained from public pharmacies. The aim was also to review data related to, in our opinion, two major drawbacks of using off-label topical drugs: safety data on the use of the final dermal preparation and scientific information relevant for the choice of a proper topical vehicle for specific drug and proper stability evaluation.
引用
收藏
页码:131 / 138
页数:8
相关论文
共 50 条
  • [31] Off-label studies on tofacitinib in dermatology: a review
    Tegtmeyer, Kyle
    Zhao, Jeffrey
    Maloney, Nolan J.
    Atassi, Giancarlo
    Beestrum, Molly
    Lio, Peter A.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2021, 32 (04) : 399 - 409
  • [32] Off-Label studies on anakinra in dermatology: a review
    Tegtmeyer, Kyle
    Atassi, Giancarlo
    Zhao, Jeffrey
    Maloney, Nolan J.
    Lio, Peter A.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (01) : 73 - 86
  • [33] Off-label studies on ruxolitinib in dermatology: a review
    Wu, Jessica
    Smogorzewski, Jan
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 606 - 612
  • [34] Off-label studies on apremilast in dermatology: a review
    Maloney, Nolan J.
    Zhao, Jeffrey
    Tegtmeyer, Kyle
    Lee, Ernest Y.
    Cheng, Kyle
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2020, 31 (02) : 131 - 140
  • [35] Off-label Prescriptions in Public Psychiatric Hospital Practice
    Andreoli, Laura
    Gaudoneix, Muriel
    Beauverie, Patrick
    de Beaurepaire, Renaud
    THERAPIE, 2013, 68 (06): : 347 - 359
  • [36] The prevalence and consequences of support for off-label Ozempic prescriptions
    Callaghan, Timothy
    Motta, Matthew
    Stein, Michael
    Goidel, Kirby
    HEALTH ECONOMICS POLICY AND LAW, 2025,
  • [38] Off-label prescriptions in Internal Medicine: difficulties involved
    Gambetti, S.
    Lupattelli, A.
    Ventura, S.
    ITALIAN JOURNAL OF MEDICINE, 2007, 1 (03) : 69 - 75
  • [39] Off-label prescriptions: are we really so inhibited?
    Scanelli, G.
    ITALIAN JOURNAL OF MEDICINE, 2007, 1 (03) : 5 - 6
  • [40] Quality of off-label prescriptions in advanced oncologic diseases
    Martin Gonzalez, Antonio
    Abajo del Alamo, Celia
    Catala Pindado, Miguel Angel
    Godoy Diez, Mercedes
    MEDICINA CLINICA, 2015, 145 (04): : 178 - 179